User profiles for James M. Brophy
james m brophyProfessor of Medicine and Epidemiology and Biostatistics, McGill University Verified email at mcgill.ca Cited by 29158 |
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents
MN Babapulle, L Joseph, P Bélisle, JM Brophy… - The Lancet, 2004 - thelancet.com
Background Drug-eluting stents (DES) are associated with lower restenosis rates than bare-metal
stents (BMS), but the benefits and safety of the new devices have not been …
stents (BMS), but the benefits and safety of the new devices have not been …
β-Blockers in congestive heart failure: a Bayesian meta-analysis
JM Brophy, L Joseph, JL Rouleau - Annals of internal medicine, 2001 - acpjournals.org
Purpose: Congestive heart failure is an important cause of patient morbidity and mortality.
Although several randomized clinical trials have compared β-blockers with placebo for …
Although several randomized clinical trials have compared β-blockers with placebo for …
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
…, L Nadeau, A Helin-Salmivaara, E Garbe, JM Brophy - bmj, 2017 - bmj.com
Objective To characterise the determinants, time course, and risks of acute myocardial
infarction associated with use of oral non-steroidal anti-inflammatory drugs (NSAIDs). Design …
infarction associated with use of oral non-steroidal anti-inflammatory drugs (NSAIDs). Design …
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive …
…, LE Levesque, JM FitzGerald, JM Brophy - Journal of the American …, 2006 - jacc.org
Objectives : The purpose of this study was to determine if statins (hydroxymethylglutaryl
CoA reductase inhibitors [HMG-CoA]), angiotensin-converting enzyme (ACE) inhibitors, and …
CoA reductase inhibitors [HMG-CoA]), angiotensin-converting enzyme (ACE) inhibitors, and …
Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding
Background: Anticoagulants and antiplatelet drugs (eg, warfarin, clopidogrel and acetylsalicylic
acid) are key therapeutic agents in the treatment of cardiovascular diseases. However, …
acid) are key therapeutic agents in the treatment of cardiovascular diseases. However, …
Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis
…, B Zhang, T Hutchinson, JM Brophy - American Journal of …, 2006 - academic.oup.com
Conventional nonsteroidal antiinflammatory drugs (NSAIDs) are associated with acute renal
failure, but cyclooxygenase-2 inhibitors have not been comparatively evaluated. The …
failure, but cyclooxygenase-2 inhibitors have not been comparatively evaluated. The …
Evidence for use of coronary stents: a hierarchical bayesian meta-analysis
JM Brophy, P Belisle, L Joseph - Annals of internal medicine, 2003 - acpjournals.org
Background: Coronary stents are widely used in interventional cardiology, but a current
quantitative systematic overview comparing routine coronary stenting with standard …
quantitative systematic overview comparing routine coronary stenting with standard …
Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review
N Dendukuri, V Costa, M McGregor, JM Brophy - Cmaj, 2005 - Can Med Assoc
Background: The recent increase in the number and severity of cases of nosocomial Clostridium
difficile-associated diarrhea (CDAD) has prompted interest in the use of probiotics for …
difficile-associated diarrhea (CDAD) has prompted interest in the use of probiotics for …
Oral fluoroquinolones and the risk of retinal detachment
Context Fluoroquinolones are commonly prescribed classes of antibiotics. Despite numerous
case reports of ocular toxicity, a pharmacoepidemiological study of their ocular safety, …
case reports of ocular toxicity, a pharmacoepidemiological study of their ocular safety, …
The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults
LE Lévesque, JM Brophy, B Zhang - Annals of Internal Medicine, 2005 - acpjournals.org
Background: Cyclooxygenase-2 (COX-2) selective inhibitors have been marketed since 1999
as safer alternatives to nonsteroidal anti-inflammatory drugs (NSAIDs). Debate about their …
as safer alternatives to nonsteroidal anti-inflammatory drugs (NSAIDs). Debate about their …